<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457456</url>
  </required_header>
  <id_info>
    <org_study_id>BM08/2011</org_study_id>
    <nct_id>NCT01457456</nct_id>
  </id_info>
  <brief_title>Biomarker for Morquio Disease</brief_title>
  <acronym>BioMorquio</acronym>
  <official_title>Biomarker for Morquio Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio
      disease from plasma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morquio syndrome (mucopolysaccharidosis type IV; MPS IV) is a mucopolysaccharide stor-age
      disease that exists in two forms (Morquio syndromes A and B) and occurs because of a
      deficiency of the enzymes N-acetyl-galactosamine-6-sulfatase and beta-galactosidase,
      respectively. A deficiency of either enzyme leads to the accumulation of mucopolysaccharides
      in the body, abnormal skeletal development, and additional symptoms. In most cases,
      individuals with Morquio syndrome have normal intelligence. The clinical features of MPS IV-B
      are less severe than those associated with MPS IV-A. Symptoms may include growth retardation,
      a prominent lower face, an abnormally short neck, knees that are abnormally close together
      (knock knees or genu valgum), flat feet, abnormal sideways and front-to-back or side-to-side
      curvature of the spine (kyphoscoliosis), abnormal development of the growing ends of the long
      bones (epiphyses) resulting in dwarfism, and/or a prominent breast bone (pectus carinatum) as
      well as bell shaped chest. Though the CNS and peripheral nerves are primarily not affected
      the bone defects may result in neurological symptoms such as spinal cord compression.

      Hearing loss, weakness of the legs, and/or additional abnormalities may also occur.

      The mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage disorders.
      Lysosomes function as the primary digestive units within cells. Enzymes within lysosomes
      break down or digest particular nutrients, such as certain carbohydrates and fats. In
      individuals with MPS disorders, deficiency or malfunction of specific lysosomal enzymes lead
      to an abnormal accumulation of certain complex carbohydrates (mucopolysaccharides or
      glyco-saminoglycans) in the arteries, skeleton, eyes, joints, ears, skin and/or teeth. These
      accumulations may also be found in the respiratory system, liver, spleen, central nervous
      system, blood, and bone marrow. This accumulation eventually causes progressive damage to
      cells, tissues, and various organ systems of the body. There are several different types and
      subtypes of mucopolysaccharidosis. These disorders, with one exception, are inherited as
      autosomal recessive traits and all vary in their clinical phenotype. Within our clinical
      trial we focus on MPS type IV.

      New methods, like mass-spectrometry give a good chance to characterize in the blood (plasma)
      of affected patents specific metabolic alterations that allow to diagnose in the future the
      disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the
      study to develop new biochemical markers from the plasma of the affected patients helping to
      benefit the patient by an early diagnose and thereby with an earlier treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio disease from plasma and saliva</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing for clinical robustness, specificity and long-term stability of the biomarker</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Morquio Disease</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients with Morquio disease at 12 months</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml EDTA
      blood,sputum tube and a dry blood spot filter card are taken. To proof the correct Morquio
      diagnosis in those patients where up to the enrollment in the study no genetic testing has
      been done, sequencing of Morquio will be done. The analyses are done in the
      Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20,
      18055 Rostock (Germany)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Morquio Disease based upon biochemical and/or genetic criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent will be obtained from the patient or the parents before any study
             related procedures.

          -  Patients older than 12 months

          -  The patient has a diagnosis of Morquio disease based upon biochemical and/or genetic
             criteria

        Exclusion Criteria:

          -  No Informed consent from the patient or the parents before any study related
             procedures.

          -  Patients younger than 12 months

          -  The patient has no diagnosis of Morquio disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albrecht Kossel Institute Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Rolfs, MD</last_name>
    <phone>49 381 494</phone>
    <phone_ext>9540</phone_ext>
    <email>arndt.rolfs@med.uni-rostock.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Zielke</last_name>
    <phone>49 381 494</phone>
    <phone_ext>4739</phone_ext>
    <email>susanne.zielke@med.uni-rostock.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric practice</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <email>benmansour_b@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinics Hospital of Ribeirao Preto- University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Marques Lourenco, MD</last_name>
      <email>charlesgenetica@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Charles Marques Lourenco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rostock, Albrecht Kossel Institute</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Rolfs, MD</last_name>
      <phone>49 381494</phone>
      <phone_ext>9540</phone_ext>
      <email>arndt.rolfs@med.uni-rostock.de</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Zielke</last_name>
      <phone>49 381 494</phone>
      <phone_ext>4739</phone_ext>
      <email>susanne.zielke@med.uni-rostock.de</email>
    </contact_backup>
    <investigator>
      <last_name>Arndt Rolfs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIRMA, University of Mumbai</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jalan, MD</last_name>
      <email>jalananil@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anil Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dhahran Health Center - Saudi Aramco Medical Services Organization</name>
      <address>
        <city>Dhahran</city>
        <zip>31311</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nouriya Al-Sannaa, MD</last_name>
      <phone>+9663 877</phone>
      <phone_ext>8290</phone_ext>
      <email>nouriya.sannaa@aramco.com</email>
    </contact>
    <investigator>
      <last_name>Nouriya Abbas Al-Sannaa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Health Institute of Serbia &quot;Dr Vukan Cupic&quot;</name>
      <address>
        <city>Belgrad</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrijan Sarajlija, MD</last_name>
      <email>adrijans2004@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrijan Sarajlija, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>India</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
  </location_countries>
  <link>
    <url>http://centogene.com</url>
    <description>Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Arndt Rolfs</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Mucopolysaccharidoses</keyword>
  <keyword>Mucopolysaccharidosis IV</keyword>
  <keyword>Carbohydrate Metabolism, Inborn Errors</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

